TABLE 2.
Patient and procedure baseline data
| Unprotected left main stem (n=54)
|
|||
|---|---|---|---|
| Criteria | BMS, n=38 | DES, n=16 | P |
| Age, years, mean ± SD | 66.8±11.9 | 67.0±10.5 | 0.786 |
| Women/men, n (%) | 12 (32)/26 (68) | 7 (44)/9 (56) | 0.534 |
| Diabetes, n (%) | 10 (26) | 4 (25) | 1.000 |
| Renal insufficiency, n (%) | 14 (37) | 6 (38) | 1.000 |
| Previous MI, n (%) | 19 (50) | 7 (44) | 0.770 |
| LVEF, %, mean ± SD | 49±16 | 54±14 | 0.295 |
| Previous cardiac surgery, n (%) | 3 (8) | 1 (6) | 1.000 |
| Cardiogenic shock, n (%) | 7 (18) | 0 (0) | 0.012* |
| Reference vessel diameter, mm, mean ± SD | 3.7±0.4 | 3.5±0.3 | 0.008* |
| Location of stent placement, n (%) | |||
| Ostial | 6 (16) | 4 (25) | 0.459 |
| Bifurcation | 18 (47) | 6 (38) | 0.561 |
| Predilation, n (%) | 31 (82) | 12 (75) | 0.714 |
| Stent diameter, mm, mean ± SD | 3.6±0.4 | 3.3±0.3 | 0.003* |
| Stent length, mm, mean ± SD | 13.0±3.7 | 13.9±9.9 | 0.038* |
| Use of glycoprotein IIb/IIIa antagonist, n (%) | 29 (76) | 13 (81) | 1.000 |
| Postprocedure stay, days, (Q1, Q3) | 5.5 (3.8, 13.0) | 4.0 (2.3, 5.0) | 0.017* |
| In-hospital events, n (%) | |||
| New MI | 0 (0) | 0 (0) | – |
| Stroke | 0 (0) | 0 (0) | – |
| Death | 4 (10.5) | 0 (0) | 0.306 |
*
P<0.05. BMS Bare metal stent; DES Drug-eluting stent; LVEF Left ventricular ejection fraction; MI Myocardial infarction; Q1 Twenty-fifth percentile; Q3 Seventy-fifth percentile